Protracted treatment with MDMA induces heteromeric nicotinic receptor up-regulation in rat brain: an autoradiography study.

Previous studies indicate that 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) can induce heteromeric nicotinic acetylcholine receptor (nAChR, mainly of α4β2 subtype) up-regulation. In this study we treated Sprague-Dawley rats twice-daily for 10 days with either saline or MDMA (7 mg/kg) and killed them on day 11 to perform [125I]epibatidine binding autoradiograms on serial coronal slices. Results showed significant increases in nAChR density in the substantia nigra, ventral tegmental area, nucleus accumbens, olfactory tubercle, anterior caudate-putamen, somatosensory cortex, motor cortex, auditory cortex, retrosplenial cortex, laterodorsal thalamus nuclei, amygdala, postsubiculum and pontine nuclei. These increases ranged from 3% (retrosplenial cortex) to 30 and 33% (amygdala and substantia nigra). No increased α4 subunit immunoreactivity was found in up-regulated areas compared with saline-treated rats, suggesting a post-translational mechanism as occurs with nicotine. The percentage of up-regulation correlated positively with the density of serotonin transporters, according to the serotonergic profile of MDMA. The heteromeric nAChR increase in concrete areas could account, at least in part, for the reinforcing, sensitizing and psychiatric disorders observed after long-term treatment with MDMA.

Development of fetal nicotine and muscarinic receptors in utero

The role of acetylcholine in the central and peripheral nervous systems is well established in adults. Cholinergic modulation of vascular functions and body fluid balance has been extensively studied. In the embryo-fetus, cholinergic receptors are widespread in the peripheral and central systems, including smooth muscle and the epithelial lining of the cardiovascular, digestive, and urinary systems, as well as in the brain. Fetal nicotine and muscarinic receptors develop in a pattern (e.g., amount and distribution) related to gestational periods. Cholinergic mechanisms have been found to be relatively intact and functional in the control of vascular homeostasis during fetal life in utero at least during the last third of gestation. This review focuses on the development of fetal nicotine and muscarinic receptors, and provides information indicating that central cholinergic systems are well developed in the control of fetal blood pressure and body fluid balance before birth. Therefore, the development of cholinergic systems in utero plays an important role in fetal vascular regulation, gastrointestinal motility, and urinary control.

Muscarinic M1, M3, Nicotinic,GABAA and GABAB Receptor Subtypes Gene Expression in Insulin Induced Hypoglycemic Rat Brain Regions: Functional Regulation through Phospholipase C and CREB Protein

In the present study, a detailed investigation on the alterations of muscarinic M1, M3, α7 nicotinic acetylcholine receptor (α7 nAchR), GABA receptors and its subtypes; GABAAα1 and GABAB in the brain regions of streptozotocin induced diabetic and insulin induced hypoglycemic rats were carried out. Gene expression of acetylcholine esterase (AChE), choline acetyltransferase (ChAT), GAD, GLUT3, Insulin receptor, superoxide dismutase (SOD), Bax protein, Phospholipase C and CREB in hypoglycemic and hyperglycemic rat brain were studied. Muscarinic M1, M3 receptors, AChE, ChAT, GABAAα1, GABAB, GAD, Insulin receptor, SOD, Bax protein and Phospholipase C expression in pancreas was also carried out. The molecular studies on the CNS and PNS damage will elucidate the therapeutic role in the corrective measures of the damage to the brain during hypoglycemia and hyperglycemia.

Role of acetylcholine receptors in proliferation and differentiation of P19 embryonal carcinoma cells

Coordinated proliferation and differentiation of progenitor cells is the base for production of appropriate numbers of neurons and glia during neuronal development in order to establish normal brain functions. We have used murine embryonal carcinoma P19 cells as an in vitro model for early differentiation to study participation of nicotinic (nAChR) and muscarinic acetylcholine (mAChR) receptors in the proliferation of neural progenitor cells and their differentiation to neurons. We have previously shown that functional nicotinic acetylcholine receptors (nAChRs) already expressed in embryonic cells mediate elevations in cytosolic free calcium concentration ([Ca2+](i)) via calcium influx through nAChR channels whereas intracellular stores contribute to nAChR- and mAChR-mediated calcium fluxes in differentiated cells [Resende et al., Cell Calcium 43 (2008) 107-121]. In the present study, we have demonstrated that nicotine provoked inhibition of proliferation in embryonic cells as determined by BrdU labeling. However, in neural progenitor cells nicotine stimulated proliferation which was reversed in the presence of inhibitors of calcium mobilization from intracellular stores, indicating that liberation of intracellular calcium contributed to this proliferation induction. Muscarine induced proliferation stimulation in progenitor cells by activation of G alpha(q/11)-coupled M-1, M-3 and M-5 receptors and intracellular calcium stores, whereas G alpha(i/o)-protein coupled M-2 receptor activity mediated neuronal differentiation. (C) 2008 Elsevier Inc. All rights reserved.

Activation of nicotinic receptor-induced postsynaptic responses to luteinizing hormone-releasing hormone in bullfrog sympathetic ganglia via a Na+-dependent mechanism

Nicotine at very low doses (5–30 nM) induced large amounts of luteinizing hormone-releasing hormone (LHRH) release, which was monitored as slow membrane depolarizations in the ganglionic neurons of bullfrog sympathetic ganglia. A nicotinic antagonist, d-tubocurarine chloride, completely and reversibly blocked the nicotine-induced LHRH release, but it did not block the nerve-firing-evoked LHRH release. Thus, nicotine activated nicotinic acetylcholine receptors and produced LHRH release via a mechanism that is different from the mechanism for evoked release. Moreover, this release was not caused by Ca2+ influx through either the nicotinic receptors or the voltage-gated Ca2+ channels because the release was increased moderately when the extracellular solution was changed into a Ca2+-free solution that also contained Mg2+ (4 mM) and Cd2+ (200 μM). The release did not depend on Ca2+ release from the intraterminal Ca2+ stores either because fura-2 fluorimetry showed extremely low Ca2+ elevation (≈30 nM) in response to nicotine (30 nM). Moreover, nicotine evoked LHRH release when [Ca2+] elevation in the terminals was prevented by loading the terminals with 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid and fura-2. Instead, the nicotine-induced release required extracellular Na+ because substitution of extracellular NaCl with N-methyl-d-glucamine chloride completely blocked the release. The Na+-dependent mechanism was not via Na+ influx through the voltage-gated Na+ channels because the release was not affected by tetrodotoxin (1–50 μM) plus Cd2+ (200 μM). Thus, nicotine at very low concentrations induced LHRH release via a Na+-dependent, Ca2+-independent mechanism.

Tonic nicotinic modulation of serotoninergic transmission in the spinal cord

The spinal serotoninergic projection from the raphe magnus has been shown to modulate nociceptive inputs, and activation of this projection mediates nicotine-elicited analgesia. Here, we investigate the interactions between cholinergic and serotoninergic systems in the spinal cord, by conducting serotonin [5-hydroxytryptamine (5-HT)] efflux experiments on mouse spinal slices. At least three spinal populations of nicotinic receptors are distinguished that affect 5-HT release. The first could be directly located on serotoninergic terminals, is insensitive to nanomolar concentrations of methyllicaconitine (MLA), and may be subjected to a basal (not maximal) cholinergic tone. The second is tonically and maximally activated by endogenous acetylcholine, insensitive to nanomolar concentrations of MLA, and present on inhibitory neurons. The last is also present on inhibitory neurons but is sensitive to nanomolar concentrations of MLA and not tonically activated by acetylcholine. Multiple nicotinic acetylcholine receptor populations thus differentially exert tonic or not tonic control on 5-HT transmission in the spinal cord. These receptors may be major targets for nicotine effects on antinociception. In addition, the presence of a tonic nicotinic modulation of 5-HT release indicates that endogenous acetylcholine plays a role in the physiological regulation of descending 5-HT pathways to the spinal cord.

Threonine-for-leucine mutation within domain M2 of the neuronal alpha(7) nicotinic receptor converts 5-hydroxytryptamine from antagonist to agonist.

A study was made of the effects of 5-hydroxytryptamine (5HT) on homomeric neuronal nicotinic receptors (nAcChoR) expressed in Xenopus oocytes after injection of cDNA encoding the wild-type chicken alpha(7) subunit. Acetylcholine (AcCho) elicited large currents (IAcCho) that were reduced by 5HT in a reversible and dose-dependent manner, with a half-inhibitory concentration (IC50) of 56 microM and a Hill coefficient (nH) of 1.2. The inhibition of IAcCho by 5HT was noncompetitive and voltage independent, a behavior incompatible with a channel blockade mechanism. 5HT alone did not elicit membrane currents in oocytes injected with the wild-type alpha(7) subunit cDNA. In contrast, 5HT elicited membrane currents (I5HT) in oocytes injected with cDNA encoding an alpha(7) mutant subunit with a threonine-for-leucine-247 substitution (L247T alpha(7)). I5HT was inhibited by the potent nicotinic receptor blockers alpha-bungarotoxin (100 nM) and methyllycaconitine (1 microM). Furthermore, the characteristics of I5HT, including its voltage dependence, were similar to those of IAcCho. The 5HT dose-I5HT response gave an apparent dissociation constant EC50 of 23.5 microM and a Hill coefficient nH of 1.7, which were not modified by the presence of AcCho. Similarly, the apparent affinity of L247T alpha(7) for AcCho as well as its cooperativity were not influenced by 5HT, indicating a lack of mutual interactions between 5HT and AcCho. These results show that 5HT is a potent noncompetitive antagonist of neuronal alpha(7) nAcChoR, but it becomes a noncompetitive agonist following mutation of the highly conserved leucine residue 247 located in the channel domain M2.

Quantal release at a neuronal nicotinic synapse from rat adrenal gland.

The neuronal nicotinic synapse in tissue slices of the adrenal medulla was studied with whole-cell patch-clamp. Excitatory postsynaptic currents (EPSCs) were evoked by local field stimulation or occurred spontaneously especially when external [K+] was increased. EPSCs were carried by channels sharing biophysical and pharmacological properties of neuronal-type nicotinic receptors (nAChRs). A single-channel conductance (gamma) of 43-45 pS was found from nonstationary variance analysis of EPSCs. Spontaneous EPSCs were tetrodotoxin-insensitive and Ca(2+)-dependent and occurred in burst-like clusters. Quantal analysis of spontaneous EPSCs gave a quantal size of 20 pA and amplitude histograms were well described by binomial models with low values of quantal content, consistent with a small number of spontaneously active release sites. However, rare large amplitude EPSCs suggest that the total number of sites is higher and that extrajunctional receptors are involved. Our estimates of quantal content and size at the chromaffin cell neuronal nicotinic synapse may be useful in characterizing central neuronal-type nicotinic receptor-mediated cholinergic synaptic transmission.

The surface accessibility of the glycine receptor M2-M3 loop is increased in the channel open state

Mutations in the extracellular M2-M3 loop of the glycine receptor (GlyR) alpha1 subunit have been shown previously to affect channel gating. In this study, the substituted cysteine accessibility method was used to investigate whether a structural rearrangement of the M2-M3 loop accompanies GlyR activation. All residues from R271C to V277C were covalently modified by both positively charged methanethiosulfonate ethyltrimethylammonium (MTSET) and negatively charged methanethiosulfonate ethylsulfonate (MTSES), implying that these residues form an irregular surface loop. The MTSET modification rate of all residues from R271C to K276C was faster in the glycine-bound state than in the unliganded state. MTSES modification of A272C, L274C, and V277C was also faster in the glycine-bound state. These results demonstrate that the surface accessibility of the M2-M3 loop is increased as the channel transitions from the closed to the open state, implying that either the loop itself or an overlying domain moves during channel activation.

Insights into the structural basis for zinc inhibition of the glycine receptor

Histidines 107 and 109 in the glycine receptor ( GlyR) alpha(1) subunit have previously been identified as determinants of the inhibitory zinc-binding site. Based on modeling of the GlyR alpha(1) subunit extracellular domain by homology to the acetylcholine-binding protein crystal structure, we hypothesized that inhibitory zinc is bound within the vestibule lumen at subunit interfaces, where it is ligated by His(107) from one subunit and His(109) from an adjacent subunit. This was tested by co-expressing alpha(1) subunits containing the H107A mutation with alpha(1) subunits containing the H109A mutation. Although sensitivity to zinc inhibition is markedly reduced when either mutation is individually incorporated into all five subunits, the GlyRs formed by the co-expression of H107A mutant subunits with H109A mutant subunits exhibited an inhibitory zinc sensitivity similar to that of the wild type alpha(1) homomeric GlyR. This constitutes strong evidence that inhibitory zinc is coordinated at the interface between adjacent alpha(1) subunits. No evidence was found for beta subunit involvement in the coordination of inhibitory zinc, indicating that a maximum of two zinc-binding sites per alpha(1)beta receptor is sufficient for maximal zinc inhibition. Our data also show that two zinc-binding sites are sufficient for significant inhibition of alpha(1) homomers. The binding of zinc at the interface between adjacent alpha(1) subunits could restrict intersubunit movements, providing a feasible mechanism for the inhibition of channel activation by zinc.

Identification of cholinoceptive glycinergic neurons in the mammalian retina

The light-evoked release of acetylcholine (ACh) affects the responses of many retinal ganglion cells, in part via nicotinic acetylcholine receptors (nAChRs). nAChRs that contain beta2alpha3 neuronal nicotinic acetylcholine receptors have been identified and localized in the rabbit retina; these nAChRs are recognized by the monoclonal antibody mAb210. We have examined the expression of beta2alpha3 nAChRs by glycinergic amacrine cells in the rabbit retina and have identified different subpopulations of nicotinic cholinoceptive glycinergic cells using double and triple immunohistochemistry with quantitative analysis. Here we demonstrate that about 70% of the cholinoceptive amacrine cells in rabbit retina are glycinergic cells. At least three nonoverlapping subpopulations of mAb210 glycine-immunoreactive cells can be distinguished with antibodies against calretinin, calbindin, and gamma-aminobutyric acid (GABA)(A) receptors. The cholinergic cells in rabbit retina are thought to synapse only on other cholinergic cells and ganglion cells. Thus, the expression of beta2alpha3 nAChRs on diverse populations of glycinergic cells is puzzling. To explore this finding, the subcellular localization of beta2alpha3 was studied at the electron microscopic level. mAb210 immunoreactivity was localized on the dendrites of amacrines and ganglion cells throughout the inner plexiform layer, and much of the labeling was not associated with recognizable synapses. Thus, our findings indicate that ACh in the mammalian retina may modulate glycinergic circuits via extrasynaptic beta2alpha3 nAChRs. (C) 2002 Wiley-Liss, Inc.

Functional significance of adenosine in carotid body chemosensory activity in control and chronically hypoxic animals

ABSTRACT: Carotid bodies (CB) are peripheral chemoreceptor organs sensing changes in arterial blood O2, CO2 and pH levels. Hypoxia and acidosis or hypercapnia activates CB chemoreceptor cells, which respond by releasing neurotransmitters in order to increase the action potential frequency in their sensory nerve, the carotid sinus nerve (CSN). CSN activity is integrated in the brainstem to induce a fan of cardiorespiratory reflex responses, aimed at normalising the altered blood gases. Exogenously applied adenosine (Ado) increases CSN chemosensory activity inducing hyperventilation through activation of A2 receptors. The importance of the effects of adenosine in chemoreception was reinforced by data obtained in humans, in which the intravenous infusion of Ado causes hyperventilation and dyspnoea, an effect that has been attributed to the activation of CB because Ado does not cross blood-brain barrier and because the ventilatory effects are higher the closer to the CB it is injected. The present work was performed in order to establish the functional significance of adenosine in chemoreception at the carotid body in control and chronically hypoxic rats. To achieve this objective we investigated: 1) The release of adenosine from a rat carotid body in vitro preparation in response to moderate hypoxia and the specificity of this release. We also investigated the metabolic pathways of adenosine production and release in the organ in normoxia and hypoxia; 2) The modulation of adenosine/ATP release from rat carotid body chemoreceptor cells by nicotinic ACh receptors; 3) The effects of caffeine on peripheral control of breathing and the identity of the adenosine receptors involved in adenosine and caffeine effects on carotid body chemoreceptors; 4) The interactions between dopamine D2 receptors and adenosine A2B receptors that modulate the release of catecholamines (CA) from the rat carotid body; 5) The effect of chronic caffeine intake i.e. the continuous blockage of adenosine receptors thereby simulating a caffeine dependence, on the carotid body function in control and chronically hypoxic rats. The methodologies used in this work included: molecular biology techniques (e.g. immunocytochemistry and western-blot), biochemical techniques (e.g. neurotransmitter quantification by HPLC, bioluminescence and radioisotopic methods), electrophysiological techniques (e.g. action potential recordings) and ventilatory recordings using whole-body plethysmography. It was observed that: 1) CB chemoreceptor sensitivity to hypoxia could be related to its low threshold for the release of adenosine because moderate acute hypoxia (10% O2) increased adenosine concentrations released from the CB by 44% but was not a strong enough stimulus to evoke adenosine release from superior cervical ganglia and arterial tissue; 2) Acetylcholine (ACh) modulates the release of adenosine/5’-adenosine triphosphate (ATP) from CB in moderate hypoxia through the activation of nicotinic receptors with α4 and ß2 receptor subunits, suggesting that the excitatory role of ACh in chemosensory activity includes indirect activation of purinergic receptors by adenosine and ATP, which strongly supports the hypothesis that ATP/adenosine are important mediators in chemotransduction; 3) adenosine increases the release of CA from rat CB chemoreceptor cells via A2B receptors; 4) the inhibitory effects of caffeine on CB chemoreceptors are mediated by antagonism of postsynaptic A2A and presynaptic A2B adenosine receptors indicating that chemosensory activity elicited by hypoxia is controlled by adenosine; 5) The release of CA from rat CB chemoreceptor cells is modulated by adenosine through an antagonistic interaction between A2B and D2 receptors, for the first time herein described; 6) chronic caffeine treatment did not significantly alter the basal function of CB in normoxic rats assessed as the dynamics of their neurotransmitters, dopamine, ATP and adenosine, and the CSN chemosensory activity. In contrast, the responses to hypoxia in these animals were facilitated by chronic caffeine intake because it increased the ventilatory response, slightly increased CSN chemosensory activity and increased dopamine (DA) and ATP release; 7) In comparison with normoxic rats, chronically hypoxic rats exhibited an increase in several parameters: ventilatory hypoxic response; basal and hypoxic CSN activity; tyrosine hydroxylase expression, CA content, synthesis and release; basal and hypoxic adenosine release; and in contrast a normal basal release and diminished hypoxia-induced ATP release; 8) Finally, in contrast to chronically hypoxic rats, chronic caffeine treatment did not alter the basal CSN chemosensory activity. Nevertheless, the responses to mild and intense hypoxia, and hypercapnia, were diminished. This inhibitory effect of chronic caffeine in CB output is compensated by central mechanisms, as the minute ventilation parameter in basal conditions and in response to acute hypoxic challenges remained unaltered in rats exposed to chronic hypoxia. We can conclude that adenosine both in acute and chronically hypoxic conditions have an excitatory role in the CB chemosensory activity, acting directly on adenosine A2A receptors present postsynaptically in CSN, and acting presynaptically via A2B receptors controlling the release of dopamine in chemoreceptor cells. We suggest that A2B -D2 adenosine / dopamine interactions at the CB could explain the increase in CA metabolism caused by chronic ingestion of caffeine during chronic hypoxia. It was also concluded that adenosine facilitates CB sensitisation to chronic hypoxia although this effect is further compensated at the central nervous system.-------- RESUMO: Os corpos carotídeos (CB) são pequenos orgãos emparelhados localizados na bifurcação da artéria carótida comum. Estes órgãos são sensíveis a variações na PaO2, PaCO2, pH e temperatura sendo responsáveis pela hiperventilação que ocorre em resposta à hipóxia, contribuindo também para a hiperventilação que acompanha a acidose metabólica e respiratória. As células quimiorreceptoras (tipo I ou glómicas) do corpo carotídeo respondem às variações de gases arteriais libertando neurotransmissores que activam as terminações sensitivas do nervo do seio carotídeo (CSN) conduzindo a informação ao centro respiratório central. Está ainda por esclarecer qual o neurotransmissor (ou os neurotransmissores) responsável pela sinalização hipóxica no corpo carotídeo. A adenosina é um neurotransmissor excitatório no CB que aumenta a actividade eléctrica do CSN induzindo a hiperventilação através da activação de receptores A2. A importância destes efeitos da adenosina na quimiorrecepção, descritos em ratos e gatos, foi reforçada por resultados obtidos em voluntários saudáveis onde a infusão intravenosa de adenosina em induz hiperventilação e dispneia, efeito atribuído a uma activação do CB uma vez que a adenosina não atravessa a barreira hemato-encefálica e o efeito é quanto maior quanto mais perto do CB for a administração de adenosina. O presente trabalho foi realizado com o objectivo de esclarecer qual o significado funcional da adenosina na quimiorrecepção no CB em animais controlo e em animais submetidos a hipoxia crónica mantida. Para alcançar este objectivo investigou-se: 1) o efeito da hipóxia moderada sobre a libertação de adenosina numa preparação in vitro de CB e a especificidade desta mesma libertação comparativamente com outros tecidos não quimiossensitivos, assim como as vias metabólicas de produção e libertação de adenosina no CB em normoxia e hipóxia; 2) a modulação da libertação de adenosina/ATP das células quimiorreceptoras do CB por receptores nicotínicos de ACh; 3) os efeitos da cafeína no controlo periférico da ventilação e a identidade dos receptores de adenosina envolvidos nos efeitos da adenosina e da cafeína nos quimiorreceptores do CB; 4) as interacções entre os receptores D2 de dopamina e os receptores A2B de adenosina que modulam a libertação de catecolaminas (CA) no CB de rato e; 5) o efeito da ingestão crónica de cafeína, isto é, o contínuo bloqueio e dos receptores de adenosina, simulando assim o consumo crónico da cafeína, tal como ocorre na população humana mundial e principalmente no ocidente, na função do corpo carotídeo em ratos controlo e em ratos submetidos a hipoxia crónica. Os métodos utilizados neste trabalho incluíram: técnicas de biologia molecular como imunocitoquímica e western-blot; técnicas bioquímicas, tais como a quantificação de neurotransmissores por HPLC, bioluminescência e métodos radioisotópicos; técnicas electrofisiológicas como o registro de potenciais eléctricos do nervo do seio carotídeo in vitro; e registros ventilatórios in vivo em animais não anestesiados e em livre movimento (pletismografia). Observou-se que: 1) a especificidade dos quimiorreceptores do CB como sensores de O2 está correlacionada com o baixo limiar de libertação de adenosina em resposta à hipóxia dado que a libertação de adenosina do CB aumenta 44% em resposta a uma hipóxia moderada (10% O2), que no entanto não é um estímulo suficientemente intenso para evocar a libertação de adenosina do gânglio cervical superior ou do tecido arterial. Observou-se também que aproximadamente 40% da adenosina libertada pelo CB provém do catabolismo extracelular do ATP quer em normóxia quer em hipóxia moderada, sendo que PO2 reduzidas induzem a libertação de adenosina via activação do sistema de transporte equilibrativo ENT1. 2) a ACh modula a libertação de adenosina /ATP do CB em resposta à hipoxia moderada sugerindo que o papel excitatório da ACh na actividade quimiossensora inclui a activação indirecta de receptores purinérgicos pela adenosina e ATP, indicando que a adenosina e o ATP poderiam actuar como mediadores importantes no processo de quimiotransducção uma vez que: a) a activação dos receptores nicotínicos de ACh no CB em normóxia estimula a libertação de adenosina (max 36%) provindo aparentemente da degradação extracelular do ATP. b) a caracterização farmacológica dos receptores nicotínicos de ACh envolvidos na estimulação da libertação de adenosina do CB revelou que os receptores nicotínicos de ACh envolvidos são constituídos por subunidades α4ß2. 3) a adenosina modula a libertação de catecolaminas das células quimiorreceptoras do CB através de receptores de adenosina A2B dado que: a)a cafeína, um antagonista não selectivo dos receptores de adenosina, inibiu a libertação de CA quer em normóxia quer em resposta a estímulos de baixa intensidade sendo ineficaz na libertação induzida por estímulos de intensidade superior; b) o DPCPX e do MRS1754 mimetizaram os efeitos da cafeína no CB sendo o SCH58621 incapaz de induzir a libertação de CA indicando que os efeitos da cafeína seriam mediados por receptores A2B de adenosina cuja presença nas células quimiorreceptoras do CB demonstramos por imunocitoquímica. 4) a aplicação aguda de cafeína inibiu em 52% a actividade quimiossensora do CSN induzida pela hipóxia sendo este efeito mediado respectivamente por receptores de adenosina A2A pós-sinápticos e A2B pré-sinápticos indicando que a actividade quimiossensora induzida pela hipóxia é controlada pela adenosina. 5) existe uma interacção entre os receptores A2B e D2 que controla a libertação de CA do corpo carotídeo de rato uma vez que: a) os antagonistas dos receptores D2, domperidona e haloperidol, aumentaram a libertação basal e evocada de CA das células quimiorreceptoras confirmando a presença de autorreceptores D2 no CB de rato que controlam a libertação de CA através de um mecanismo de feed-back negativo. b) o sulpiride, um antagonista dos receptores D2, aumentou a libertação de CA das células quimiorreceptoras revertendo o efeito inibitório da cafeína sobre esta mesma libertação; c) a propilnorapomorfina, um agonista D2 inibiu a libertação basal e evocada de CA sendo este efeito revertido pela NECA, um agonista dos receptores A2B. O facto de a NECA potenciar o efeito do haloperidol na libertação de CA sugere que a interacção entre os receptores D2 e A2B poderia também ocorrer ao nível de segundos mensageiros, como o cAMP. 6) a ingestão crónica de cafeína em ratos controlo (normóxicos) não alterou significativamente a função basal do CB medida como a dinâmica dos seus neurotransmissores, dopamina, ATP e adenosina e como actividade quimiossensora do CSN. Contrariamente aos efeitos basais, a ingestão crónica de cafeína facilitou a resposta à hipóxia, dado que aumentou o efeito no volume minuto respiratórioapresentando-se também uma clara tendência para aumentar a actividade quimiossensora do CSN e aumentar a libertação de ATP e dopamina.7) após um período de 15 dias de hipóxia crónica era evidente o fenómeno de aclimatização dado que as respostas ventilatórias à hipóxia se encontram aumentadas, assim como a actividade quimiossensora do CSN basal e induzida pela hipóxia. As alterações observadas no metabolismo da dopamina, assim como na libertação basal de dopamina e de adenosina poderiam contribuir para a aclimatização durante a hipoxia crónica. A libertação aumentada de adenosina em resposta à hipóxia aguda em ratos hipóxicos crónicos sugere um papel da adenosina na manutenção/aumento das respostas ventilatórias à hipóxia aguda durante a hipóxia crónica. Observou-se também que a libertação de ATP induzida pela hipóxia aguda se encontra diminuída em hipóxia crónica, contudo a ingestão crónica de cafeína reverteu este efeito para valores similares aos valores controlo, sugerindo que a adenosina possa modular a libertação de ATP em hipóxia crónica. 8) a ingestão crónica de cafeína em ratos hipóxicos crónicos induziu o aumento do metabolismo de CA no CB, medido como expressão de tirosina hidroxilase, conteúdo, síntese e libertação de CA. 9) a ingestão crónica de cafeína não provocou quaisquer alterações na actividade quimiossensora do CSN em ratos hipóxicos crónicos no entanto, as respostas do CSN à hipóxia aguda intensa e moderada e à hipercapnia encontram-se diminuídas. Este efeito inibitório que provém da ingestão crónica de cafeína parece ser compensado ao nível dos quimiorreceptores centrais dado que os parâmetros ventilatórios em condições basais e em resposta à hipoxia aguda não se encontram modificados em ratos expostos durante 15 dias a uma atmosfera hipóxica. Resumindo podemos assim concluir que a adenosina quer em situações de hipoxia aguda quer em condições de hipoxia crónica tem um papel excitatório na actividade quimiossensora do CB actuando directamente nos receptores A2A presentes pós-sinapticamente no CSN, assim como facilitando a libertação de dopamina pré-sinapticamente via receptores A2B presentes nas células quimiorreceptoras. A interacção negativa entre os receptores A2B e D2 observadas nas células quimiorreceptoras do CB poderia explicar o aumento do metabolismo de CA observado após a ingestão crónica de cafeína em animais hipóxicos. Conclui-se ainda que durante a aclimatização à hipóxia a acção inibitória da cafeína, em termos de resposta ventilatória, mediada pelos quimiorreceptores periféricos é compensada pelos efeitos excitatórios desta xantina ao nível do quimiorreceptores centrais.------- RESUMEN Los cuerpos carotídeos (CB) son órganos emparejados que están localizados en la bifurcación de la arteria carótida común. Estos órganos son sensibles a variaciones en la PaO2, en la PaCO2, pH y temperatura siendo responsables de la hiperventilación que ocurre en respuesta a la hipoxia, contribuyendo también a la hiperventilación que acompaña a la acidosis metabólica y respiratoria. Las células quimiorreceptoras (tipo I o glómicas) del cuerpo carotídeo responden a las variaciones de gases arteriales liberando neurotransmissores que activan las terminaciones sensitivas del nervio del seno carotídeo (CSN) llevando la información al centro respiratorio central. Todavía esta por clarificar cual el neurotransmisor (o neurotransmisores) responsable por la señalización hipóxica en el CB. La adenosina es un neurotransmisor excitatório en el CB ya que aumenta la actividad del CSN e induce la hiperventilación a través de la activación de receptores de adenosina del subtipo A2. La importancia de estos efectos de la adenosina en la quimiorrecepción, descritos en ratas y gatos, ha sido fuertemente reforzada por resultados obtenidos en voluntarios sanos en los que la infusión intravenosa de adenosina induce hiperventilación y dispnea, efectos estés que han sido atribuidos a una activación del CB ya que la adenosina no cruza la barrera hemato-encefalica y el efecto es tanto más grande cuanto más cercana del CB es la administración. Este trabajo ha sido realizado con el objetivo de investigar cual el significado funcional de la adenosina en la quimiorrecepción en el CB en animales controlo y en animales sometidos a hipoxia crónica sostenida. Para alcanzar este objetivo se ha estudiado: 1) el efecto de la hipoxia moderada en la liberación de adenosina en una preparación in vitro de CB y la especificidad de esta liberación en comparación con otros tejidos no-quimiosensitivos, así como las vías metabólicas de producción y liberación de adenosina del órgano en normoxia y hipoxia; 2) la modulación de la liberación de adenosina/ATP de las células quimiorreceptoras del CB por receptores nicotínicos de ACh; 3) los efectos de la cafeína en el controlo periférico de la ventilación y la identidad de los receptores de adenosina involucrados en los efectos de la adenosina y cafeína en los quimiorreceptores del CB; 4) las interacciones entre los receptores D2 de dopamina y los receptores A2B de adenosina que modulan la liberación de catecolaminas (CA) en el CB de rata y; 5) el efecto de la ingestión crónica de cafeína, es decir, el bloqueo sostenido de los receptores de adenosina, simulando la dependencia de cafeína observada en la populación mundial del occidente, en la función del CB en ratas controlo y sometidas a hipoxia crónica sostenida. Los métodos utilizados en este trabajo incluirán: técnicas de biología molecular como imunocitoquímica y western-blot; técnicas bioquímicas, tales como la cuantificación de neurotransmissores por HPLC, bioluminescencia y métodos radioisotópicos; técnicas electrofisiológicas como el registro de potenciales eléctricos del nervio do seno carotídeo in vitro; y registros ventilatórios in vivo en animales no anestesiados y en libre movimiento (pletismografia). Se observó que: 1) la sensibilidad de los quimiorreceptores de CB esta correlacionada con un bajo umbral de liberación de adenosina en respuesta a la hipoxia ya que en respuesta a una hipoxia moderada (10% O2) la liberación de adenosina en el CB aumenta un 44%, sin embargo esta PaO2 no es un estimulo suficientemente fuerte para inducir la liberación de adenosina del ganglio cervical superior o del tejido arterial; se observó también que aproximadamente 40% de la adenosina liberada del CB proviene del catabolismo extracelular del ATP en normoxia y en hipoxia moderada, y que bajas PO2 inducen la liberación de adenosina vía activación del sistema de transporte equilibrativo ENT1. 2) la ACh modula la liberación de adenosina /ATP del CB en respuesta a la hipóxia moderada lo que sugiere que el papel excitatório de la ACh en la actividad quimiosensora incluye la activación indirecta de receptores purinérgicos por la adenosina y el ATP, indicando que la adenosina y el ATP pueden actuar como mediadores importantes en el proceso de quimiotransducción ya que: a) la activación de los receptores nicotínicos de ACh en el CB en normoxia estimula la liberación de adenosina (max 36%) que aparentemente proviene de la degradación extracelular del ATP. Se observó también que este aumento de adenosina en el CB en hipoxia ha sido antagonizado parcialmente por antagonistas de estos mismos receptores; b) la caracterización farmacológica de los receptores nicotínicos de ACh involucrados en la estimulación de la liberación de adenosina del CB ha revelado que los receptores nicotínicos de ACh involucrados son constituidos por sub-unidades α4ß2. 3) la adenosina modula la liberación de CA de las células quimiorreceptoras del CB a través de receptores de adenosina A2B ya que: a) la cafeína, un antagonista no selectivo de los receptores de adenosina, ha inhibido la liberación de CA en normoxia y en respuesta a estímulos de baja intensidad siendo ineficaz en la liberación inducida por estímulos de intensidad superior; b) el DPCPX y el MRS1754 ha mimetizado los efectos de la cafeína en el CB y el SCH58621 ha sido incapaz de inducir la liberación de CA lo que sugiere que los efectos de la cafeína son mediados por receptores A2B de adenosina que están localizados pré-sinapticamente en las células quimiorreceptoras del CB. 4) la aplicación aguda de cafeína ha inhibido en 52% la actividad quimiosensora del CSN inducida por la hipoxia siendo este efecto mediado respectivamente por receptores de adenosina A2A pós-sinápticos y A2B pré-sinápticos lo que indica que la actividad quimiosensora inducida por la hipoxia es controlada por la adenosina. 5) existe una interacción entre los receptores A2B y D2 que controla la liberación de CA del CB de rata ya que: a) el sulpiride, un antagonista de los receptores D2, ha aumentado la liberación de CA de las células quimiorreceptoras revertiendo el efecto inhibitorio de la cafeína sobre esta misma liberación; b) los antagonistas de los receptores D2, domperidona y haloperidol, han aumentado la liberación basal e evocada de CA de las células quimiorreceptoras confirmando la presencia de autorreceptores D2 en el CB de rata que controlan la liberación de CA a través de un mecanismo de feed-back negativo; c) la propilnorapomorfina, un agonista D2, ha inhibido la liberación basal e evocada de CA sendo este efecto revertido por la NECA, un agonista de los receptores A2B. Ya que la NECA potencia el efecto del haloperidol en la liberación de CA la interacción entre los D2 y A2B puede también ocurrir al nivel de segundos mensajeros, como el cAMP. 6) la ingestión crónica de cafeína en ratas controlo (normóxicas) no ha cambiado significativamente la función basal del CB medida como la dinámica de sus neurotransmisores, dopamina, ATP y adenosina y como actividad quimiosensora del CSN. Al revés de lo que pasa con los efectos básales, la ingestión crónica de cafeína facilitó la respuesta a la hipóxia, ya que ha aumentado la respuesta ventilatória medida como volumen minuto presentando también una clara tendencia para aumentar la actividad quimiosensora del CSN y aumentar la liberación de ATP y dopamina. 7. Después de un período de 15 días de hipoxia crónica se puede observar el fenómeno de climatización ya que las respuestas ventilatórias a la hipoxia están aumentadas, así como la actividad quimiosensora del CSN basal e inducida por la hipoxia. Los cambios observados en el metabolismo de la dopamina, así como en la liberación basal de dopamina y de adenosina podrían contribuir para la climatización en hipoxia crónica. El aumento en la liberación de adenosina en respuesta a la hipoxia aguda en ratas sometidas a hipoxia crónica sugiere un papel para la adenosina en el mantenimiento/aumento de las respuestas ventilatórias a la hipoxia aguda en hipoxia crónica sostenida. Se ha observado también que la liberación de ATP inducida por la hipoxia aguda está disminuida en hipoxia crónica y que la ingestión crónica de cafeína reverte este efecto para valores similares a los valores controlo, sugiriendo que la adenosina podría modular la liberación de ATP en hipoxia crónica. 8. la ingestión crónica de cafeína ha inducido el aumento del metabolismo de CA en el CB en ratas hipóxicas crónicas, medido como expresión de la tirosina hidroxilase, contenido, síntesis y liberación de CA. 9. la ingestión crónica de cafeína no ha inducido cambios en la actividad quimiosensora del CSN en ratas hipóxicas crónicas sin embargo las respuestas do CSN a una hipoxia intensa y moderada y a la hipercapnia están disminuidas. Este efecto inhibitorio que es debido a la ingestión crónica de cafeína es compensado al nivel de los quimiorreceptores centrales ya que los parámetros ventilatórios en condiciones básales y en respuesta a la hipoxia aguda no están modificados en ratas expuestas durante 15 días a una atmósfera hipóxica. Resumiendo se puede concluir que la adenosina en situaciones de hipoxia aguda así como en hipoxia crónica tiene un papel excitatório en la actividad quimiosensora del CB actuando directamente en los receptores A2A localizados pós-sinapticamente en el CSN, así como controlando la liberación de dopamina pré-sinaptica vía receptores A2B localizados en las células quimiorreceptoras. Las interacciones entre los receptores A2B y D2 observadas en las células quimiorreceptoras del CB podrían explicar el aumento del metabolismo de CA observado después de la ingestión crónica de cafeína en animales hipóxicos. Por fin, pero no menos importante se puede concluir que durante la climatización a la hipoxia la acción inhibitoria de la cafeína, medida como respuesta ventilatória, mediada por los quimiorreceptores periféricos es compensada por los efectos excitatórios de esta xantina al nivel de los quimiorreceptores centrales.

Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.

With the aging population and its rapidly increasing prevalence, dementia has become an important public health concern in developed and developing countries. To date, the pharmacological treatment is symptomatic and based on the observed neurotransmitter disturbances. The four most commonly used drugs are donepezil, galantamine, rivastigmine and memantine. Donepezil, galantamine and rivastigmine are acetylcholinesterase inhibitors with different pharmacodynamic and pharmacokinetic profiles. Donepezil inhibits selectively the acetylcholinesterase and has a long elimination half-life (t½) of 70 h. Galantamine is also a selective acetylcholinesterase inhibitor, but also modulates presynaptic nicotinic receptors. It has a t½ of 6-8 h. Donepezil and galantamine are mainly metabolised by cytochrome P450 (CYP) 2D6 and CYP3A4 in the liver. Rivastigmine is a so-called 'pseudo-irreversible' inhibitor of acetylcholinesterase and butyrylcholinesterase. The t½ of the drug is very short (1-2 h), but the duration of action is longer as the enzymes are blocked for around 8.5 and 3.5 h, respectively. Rivastigmine is metabolised by esterases in liver and intestine. Memantine is a non-competitive low-affinity antagonist of the NMDA receptor with a t½ of 70 h. Its major route of elimination is unchanged via the kidneys. Addressing the issue of inter-patient variability in treatment response might be of special importance for the vulnerable population taking anti-dementia drugs. Pharmacogenetic considerations might help to avoid multiple medication changes due to non-response and/or adverse events. Some pharmacogenetic studies conducted on donepezil and galantamine reported an influence of the CYP2D6 genotype on the pharmacokinetics of the drugs and/or on the response to treatment. Moreover, polymorphisms in genes of the cholinergic markers acetylcholinesterase, butyrylcholinesterase, choline acetyltransferase and paraoxonase were found to be associated with better clinical response to acetylcholinesterase inhibitors. However, confirmation studies in larger populations are necessary to establish evidence of which subgroups of patients will most likely benefit from anti-dementia drugs. The aim of this review is to summarize the pharmacodynamics and pharmacokinetics of the four commonly used anti-dementia drugs and to give an overview on the current knowledge of pharmacogenetics in this field.

Undifferentiated and differentiated PC12 cells protected by huprines against injury induced by hydrogen peroxide

Oxidative stress is implicated in the pathogenesis of neurodegenerative disorders and hydrogen peroxide (H2O2) plays a central role in the stress. Huprines, a group of potent acetylcholinesterase inhibitors (AChEIs), have shown a broad cholinergic pharmacological profile. Recently, it has been observed that huprine X (HX) improves cognition in non transgenic middle aged mice and shows a neuroprotective activity (increased synaptophysin expression) in 3xTg-AD mice. Consequently, in the present experiments the potential neuroprotective effect of huprines (HX, HY, HZ) has been analyzed in two different in vitro conditions: undifferentiated and NGF-differentiated PC12 cells. Cells were subjected to oxidative insult (H2O2, 200 µM) and the protective effects of HX, HY and HZ (0.01 µM- 1 µM) were analyzed after a pre-incubation period of 24 and 48 hours. All huprines showed protective effects in both undifferentiated and NGF-differentiated cells, however only in differentiated cells the effect was dependent on cholinergic receptors as atropine (muscarinic antagonist, 0.1 µM) and mecamylamine (nicotinic antagonist, 100 µM) reverted the neuroprotection action of huprines. The decrease in SOD activity observed after oxidative insult was overcome in the presence of huprines and this effect was not mediated by muscarinic or nicotinic receptors. In conclusion, huprines displayed neuroprotective properties as previously observed in in vivo studies. In addition, these effects were mediated by cholinergic receptors only in differentiated cells. However, a non-cholinergic mechanism, probably through an increase in SOD activity, seems to be also involved in the neuroprotective effects of huprines.

Evaluation of the cholinomimetic actions of trimethylsulfonium, a compound present in the midgut gland of the sea hare Aplysia brasiliana (Gastropoda, Opisthobranchia)

Trimethylsulfonium, a compound present in the midgut gland of the sea hare Aplysia brasiliana, negatively modulates vagal response, indicating a probable ability to inhibit cholinergic responses. In the present study, the pharmacological profile of trimethylsulfonium was characterized on muscarinic and nicotinic acetylcholine receptors. In rat jejunum the contractile response induced by trimethylsulfonium (pD2 = 2.46 ± 0.12 and maximal response = 2.14 ± 0.32 g) was not antagonized competitively by atropine. The maximal response (Emax) to trimethylsulfonium was diminished in the presence of increasing doses of atropine (P<0.05), suggesting that trimethylsulfonium-induced contraction was not related to muscarinic stimulation, but might be caused by acetylcholine release due to presynaptic stimulation. Trimethylsulfonium displaced [³H]-quinuclidinyl benzilate from rat cortex membranes with a low affinity (Ki = 0.5 mM). Furthermore, it caused contraction of frog rectus abdominis muscles (pD2 = 2.70 ± 0.06 and Emax = 4.16 ± 0.9 g), which was competitively antagonized by d-tubocurarine (1, 3 or 10 µM) with a pA2 of 5.79, suggesting a positive interaction with nicotinic receptors. In fact, trimethylsulfonium displaced [³H]-nicotine from rat diaphragm muscle membranes with a Ki of 27.1 µM. These results suggest that trimethylsulfonium acts as an agonist on nicotinic receptors, and thus contracts frog skeletal rectus abdominis muscle and rat jejunum smooth muscle via stimulation of postjunctional and neuronal prejunctional nicotinic cholinoreceptors, respectively.